![]() ![]() "But we found that the cells in that tissue are still very viable. "That tissue is always a bit frilly and is normally discarded," Dr. RECLAIM's innovation starts with saving the patient's debrided tissue. "We wanted to improve this technique because during the waiting period, the patient's life is on hold, costs increase and the logistics can be complex," Dr. The biopsy is cultured in an outside laboratory, and the cultured cells are implanted weeks later. ![]() ![]() Recycling patient cellsĮxisting cell therapy to repair knee cartilage generally involves surgically debriding the cartilage defect and then taking a biopsy of healthy cartilage from the patient. The procedure might be suitable for nonarthritic patients ages 18 to 50 who have fresh cartilage defects. RECLAIM is used to repair symptomatic cartilage defects, usually resulting from trauma or an athletic injury. Planning is underway for a clinical trial at Mayo Clinic. "The results, about four years out, are very good - comparable to or better than other cell therapies, except these patients achieve normal function after surgery about six months more quickly," he says. Saris previously performed the RECLAIM cartilage repair technique in Europe. The procedure can be completed in a single surgery.ĭr. This method is under study in clinical trials for the treatment of several types of cancer, including myeloma.RECLAIM mixes chondrons from debrided tissue with donor autologous stem cells to create a biologic filler for the repair of damaged knee cartilage. After the second course, the other half of the healthy stem cells that were originally removed are infused. Usually, several weeks or months pass before the second course of high-dose chemotherapy. After the first transplant, half of these stem cells are infused into the patient’s body. All the stem cells are collected from the patient before the first-high dose chemotherapy treatment. Others may have a transplant called a “tandem transplant.” A tandem transplant involves a planned second autologous stem cell transplant after the first autologous transplant. Tandem transplant. Most people have a single autologous transplant. Doesn't carry the risk of graft-versus-host-disease.Doesn't offer the benefits of graft-versus-tumor (GVT) effect, when healthy donor cells attack cancer cells. As a result, there is a higher risk of relapse of the disease.Unlike allogeneic stem cell transplant, this procedure: This is called “engraftment.” Engraftment occurs more quickly in an autologous transplantation than in an allogeneic transplantation because the frozen cells are the patient’s own stem cells, so graft failure (when the transplanted cells do not successfully grow and divide in the bone marrow) is rare, and graft-versus-host disease (GVHD) is never a problem. That is why the stem cells are removed before the treatment, so they can be treated outside of the body and reinfused after the treatment to make new blood cells in the bone marrow. This type of transplant is often used to treat blood cancers such as Hodgkin lymphoma, non-Hodgkin lymphoma and myeloma.Īn autologous stem cell transplant's goal is to restore the body's ability to make normal blood cells after high-dose chemotherapy or radiation. Such intensive treatments usually destroy cancer cells better than standard treatments, but these high-dose treatments are toxic and also destroy the blood-producing stem cells in the bone marrow. After the patient undergoes high doses of chemotherapy, either with or without radiation therapy, the stem cells are then returned to the body. In autologous stem cell transplantation, the procedure uses the patient’s own stem cells for the transplant. The stem cells are collected from the patient in advance and are frozen. The Trish Greene Back to School Program. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |